期刊文献+

基于多标记学习预测药物-靶标相互作用 被引量:5

Predicting drug-target interactions with multi-label learning
在线阅读 下载PDF
导出
摘要 对药物-靶标关联进行了研究,提出基于弱标记和多信息融合的药物-靶标相互作用预测方法 PDML。通过与其他方法对比和数据库检索验证评估PDML模型的性能:与Yamanishi提出的方法、RLSMDA、Lap RLS及Net CBP相比,除在核受体数据集中该方法在AUC上的性能比Lap RLS略有降低之外,模型在敏感性、特异性、AUC和AUPR上的性能均优于其他四种方法;提取前5个预测分值最高的药物-靶标对,这些药物-靶标对能通过检索Drug Bank、Super Target和KEGG数据库而得到验证。 Drug-target association prediction is researched.PDML based on weak label learning and multi-informationfusion is proposed to find new drug-target interactions from human enzymes,ion channels,GPCRs and nuclear receptors.The performance of the proposed method makes better than the methods provided by Yamanishi,RLSMDA,LapRLS andNetCBP in terms of sensitivity,specificity,AUC values and AUPR values except that the AUC values of the model slightlydecrease in nuclear receptor dataset compared to LapRLS.The five drug-target interaction pairs with highest scores can beextracted and validated by available public database DrugBank,SuperTarget and KEGG.
作者 彭利红 刘海燕 任日丽 马俊 王建芬 PENG Lihong;LIU Haiyan;REN Rili;MA Jun;WANG Jianfen(College of Information Engineering, Changsha Medical University, Changsha 410219, China;College of Pharmacy, Changsha Medical University, Changsha 410219, China)
出处 《计算机工程与应用》 CSCD 北大核心 2017年第15期260-265,共6页 Computer Engineering and Applications
基金 湖南省教育厅优秀青年项目(No.14B023) 湖南省教育厅一般项目(No.13C1108 No.14C0115)
关键词 药物-靶标相互作用 多标记学习 多信息融合 药物-靶标相互作用网络 药物相似性 drug-target interaction multi-label learning multi-information fusion drug-target interaction network drug similarity
  • 相关文献

参考文献1

二级参考文献32

  • 1Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor [J]. Cardiovasc Drug Rev, 2002, 20: 303-328.
  • 2Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts [J]. Drug Discov Today, 2007, 12: 34-42.
  • 3Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands [J]. Drug Discov Today, 2004, 9: 641-651.
  • 4Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study [J]. JAMA, 2000, 284: 1247-1255.
  • 5Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial [J]. JAMA, 2000, 5, 283: 1695-1702.
  • 6Gore M, Carmichael J, Gordon A, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J]. J Clin Oncol, 1997, 15: 2183-2193.
  • 7Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy [J]. Trends Mol Med, 2002, 8(4 Suppl): S14-18.
  • 8Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and an giogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor [J]. Clin Cancer Res, 2001, 7: 1459.
  • 9Terre C, Eclache V, Rousselot P. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia [J]. Leukemia, 2004, 18: 1340-1346.
  • 10LiHL WangCM.Analysis of mutations of bcr-abl gene and P53 gene in different phases of chronic myelogenous leukemia .兰州大学学报:自然科学版,2002,38:96-99.

共引文献13

同被引文献42

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部